Glaukos Corp (STU:6GJ)
€ 119 0 (0%) Market Cap: 6.82 Bil Enterprise Value: 6.73 Bil PE Ratio: 0 PB Ratio: 11.05 GF Score: 64/100

Glaukos Corp at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 01:15AM GMT
Release Date Price: €79 (+8.22%)
Unidentified Participant

Hi, sorry about that. So let's get started. It's closing out this Tuesday. I'm really happy to be introducing members of the management team of Glaukos. We have CEO, Tom Burns; COO, Joe Gilliam; and Alex Thurman, CFO. So we're starting some prepared remarks and then I will join them for a Q&A.

Tom Burns
Glaukos Corporation - Chairman & CEO

Okay. Thank you. Good evening and thank you for coming here tonight to learn more about Glaukos. Our founding mission at Glaukos has been a device -- a facile implantable injectable procedure that could liberate glaucoma patients from a lifelong consignment to glaucoma for topical drop therapy.

And in doing so, we have really had been from the very beginning -- it's been our birth right -- has been interventional glaucoma. From the beginning, we sought to transform glaucoma therapy by devising a portfolio of products that would treat patients across the full range of glaucoma disease stage severity.

Our two major products within the first five years were iStent and iStent inject,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot